Digestive Disease Interventions
DOI: 10.1055/s-0043-1771313
Review Article

Interventional Radiology Management of Advanced Schistosomiasis: State of the Art

1   Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil
Rômulo Florêncio Tristão dos Santos
1   Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil
Denis Szejnfeld
1   Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil
Gloria Maria Martinez Salazar
2   Division of Vascular Interventional Radiology, Department of Radiology, UNC Chapel Hill, Chapel Hill, North Carolina
› Author Affiliations


Advanced schistosomiasis is an infectious disease, endemic in some regions, with long-term implications for patient care. It can be associated with conditions such as portal hypertension, variceal hemorrhage, chronic hepatic encephalopathy, and hepatocellular carcinoma. In this article, an overview of the most recent data about the role of interventional radiology in the management of these conditions will be presented, as well as the authors' experience on interventional management of schistosomiasis patients.

Financial Source

None declared.

Publication History

Received: 29 September 2022

Accepted: 15 June 2023

Article published online:
28 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet 2014; 383 (9936): 2253-2264
  • 2 Vos T, Afshin A, Aiyar S. et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1211-1259
  • 3 Warren KS. Schistosomiasis: host-pathogen biology. Rev Infect Dis 1982; 4 (04) 771-775
  • 4 Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 2004; 17 (05) 439-447
  • 5 Manzella A, Ohtomo K, Monzawa S, Lim JH. Schistosomiasis of the liver. Abdom Imaging 2008; 33 (02) 144-150
  • 6 Bustinduy AL, King CH. , et al. Schistosomiasis. Manson's Tropical Diseases. 23rd ed. Edinburgh: Elsevier; 2013:698–725
  • 7 Strickland GT, Abdel-Warib ME. . Schistosomiasis. In: Strickland GT, ed. Hunter's Tropical Medicine. 7th ed. Philadelphia: WB Saunders; 1991:781–802.
  • 8 Andrade ZA. Pathology of human schistosomiasis. Mem Inst Oswaldo Cruz 1987; 82 (Suppl 4): 17-23
  • 9 Monzawa S, Uchiyama G, Ohtomo K, Araki T. Schistosomiasis japonica of the liver: contrast-enhanced CT findings in 113 patients. AJR Am J Roentgenol 1993; 161 (02) 323-327
  • 10 Yosry A. Schistosomiasis and neoplasia. Contrib Microbiol 2006; 13: 81-100
  • 11 Abdel-Rahim AY. Parasitic infections and hepatic neoplasia. Dig Dis 2001; 19 (04) 288-291
  • 12 Kojiro M, Kakizoe S, Yano H, Tsumagari J, Kenmochi K, Nakashima T. Hepatocellular carcinoma and schistosomiasis japonica. A clinicopathologic study of 59 autopsy cases of hepatocellular carcinoma associated with chronic schistosomiasis japonica. Acta Pathol Jpn 1986; 36 (04) 525-532
  • 13 Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop 2000; 77 (01) 111-131
  • 14 de Franchis R, Baveno V. Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53 (04) 762-768
  • 15 Groszmann RJ, Garcia-Tsao G, Bosch J. et al; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353 (21) 2254-2261
  • 16 Wang DW, Qian YN, Liu CY, Shao JM. [A survey of advanced schistosomiasis patients with upper gastrointestinal bleeding]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1989; 7 (02) 119-121
  • 17 Coelho FF, Perini MV, Kruger JA. et al. Management of variceal hemorrhage: current concepts. Arq Bras Cir Dig 2014; 27 (02) 138-144
  • 18 Merli M, Nicolini G, Angeloni S. et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003; 38 (03) 266-272
  • 19 Bittencourt PL, Farias AQ, Strauss E, Mattos AA. Panel of the 1st Brazilian Consensus of Variceal Bleeding, Brazilian Society of Hepatology. Variceal bleeding: consensus meeting report from the Brazilian Society of Hepatology. Arq Gastroenterol 2010; 47 (02) 202-216
  • 20 Raia S, Mies S, Macedo AL. Surgical treatment of portal hypertension in schistosomiasis. World J Surg 1984; 8 (05) 738-752
  • 21 Ferraz AAB, Lopes EPA, Bacelar TS. et al. Tratamento cirúrgico da hipertensão portal esquistossomótica no hc/UFPE: análise de 131 casos. Rev Col Bras Cir 2000; 27 (05) 332-337
  • 22 Makdissi FF, Herman P, Pugliese V. et al. Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension. World J Surg 2010; 34 (11) 2682-2688
  • 23 Farias AQ, Kassab F, da Rocha EC. et al. Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 2009; 24 (12) 1852-1856
  • 24 Haddad CM, Neto AD, Richieri Tda S. et al. Tratamento cirúrgico da hemorragia aguda por varizes esofagogástricas (Operação de Boerema-Crile Jr). Rev Assoc Med Bras 1975; 21 (03) 81-84
  • 25 Sakai P. [Endoscopic sclerosis of esophageal varices after surgical treatment of portal hypertension in patient with hepatosplenic schistosomiasis]. Arq Gastroenterol 2001; 38 (02) 81-83
  • 26 Petroianu A. [Surgical treatment of portal hypertension in schistosomiasis mansoni]. Rev Soc Bras Med Trop 2003; 36 (02) 253-265
  • 27 Raia S, da Silva LC, Gayotto LC, Forster SC, Fukushima J, Strauss E. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20 (02) 398-403
  • 28 D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev 2010; 2010 (03) CD002233
  • 29 Corbett C, Mangat K, Olliff S, Tripathi D. The role of transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of variceal hemorrhage. Liver Int 2012; 32 (10) 1493-1504
  • 30 Dondelinger RF, El-Kadi MH, Taema M. , et al. TIPS in Egyptian hepatic schistosomiasis. In: Rossi P, Ricci P, Broglia L. Portal Hypertension. Diagnostic Imaging and Imaging-Guided Therapy. Berlin, Heidelberg: Springer; 2000:249–263
  • 31 Deng D, Liao MS, Qin JP, Li XA. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int 2006; 5 (02) 232-236
  • 32 Kraef C, Arand J, Galaski J. et al. Transjugular intrahepatic portosystemic shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. Travel Med Infect Dis 2019; 30: 130-132
  • 33 Rosemurgy AS, Frohman HA, Teta AF, Luberice K, Ross SB. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. J Am Coll Surg 2012; 214 (04) 445-453 , discussion 453–455
  • 34 Khanna R, Sarin SK. Non-cirrhotic portal hypertension - diagnosis and management. J Hepatol 2014; 60 (02) 421-441
  • 35 Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51 (01) 306
  • 36 Richter J, Bode JG, Blondin D. et al. Severe liver fibrosis caused by Schistosoma mansoni: management and treatment with a transjugular intrahepatic portosystemic shunt. Lancet Infect Dis 2015; 15 (06) 731-737
  • 37 Andersson KL, Chung RT. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007; 10 (06) 504-512
  • 38 Liu J, Zhou B, Chen D. et al. Transjugular intrahepatic portosystemic shunt placement in patients with schistosomiasis-induced liver fibrosis. Cardiovasc Intervent Radiol 2019; 42 (12) 1760-1770
  • 39 Nordmann T, Schlabe S, Feldt T. et al. TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis - a case series and review of the literature. PLoS Negl Trop Dis 2021; 15 (12) e0010065
  • 40 Strauss E, Valla D. Non-cirrhotic portal hypertension -- concept, diagnosis and clinical management. Clin Res Hepatol Gastroenterol 2014; 38 (05) 564-569
  • 41 de Franchis R, Abraldes JG, Bajaj J. et al; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
  • 42 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65 (01) 310-335
  • 43 Praktiknjo M, Simón-Talero M, Römer J. et al; Baveno VI-SPSS Group of the Baveno Cooperation. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol 2020; 72 (06) 1140-1150
  • 44 Lynn AM, Singh S, Congly SE. et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl 2016; 22 (06) 723-731
  • 45 Zidi SH, Zanditenas D, Gelu-Siméon M. et al. Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shunts. Liver Int 2007; 27 (10) 1389-1393
  • 46 Laleman W, Simon-Talero M, Maleux G. et al; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57 (06) 2448-2457
  • 47 Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature. J Vasc Interv Radiol 2007; 18 (04) 463-481
  • 48 Kimura F, Itoh H, Ambiru S. et al. Long-term results of initial and repeated partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura. AJR Am J Roentgenol 2002; 179 (05) 1323-1326
  • 49 Miyazaki M, Itoh H, Kaiho T. et al. Partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura. AJR Am J Roentgenol 1994; 163 (01) 123-126
  • 50 Stanley P, Shen TC. Partial embolization of the spleen in patients with thalassemia. J Vasc Interv Radiol 1995; 6 (01) 137-142
  • 51 Dent D, Alsabrook G, Erickson BA. et al. Blunt splenic injuries: high nonoperative management rate can be achieved with selective embolization. J Trauma 2004; 56 (05) 1063-1067
  • 52 Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology 2002; 49 (47) 1445-1448
  • 53 Pålsson B, Hallén M, Forsberg AM, Alwmark A. Partial splenic embolization: long-term outcome. Langenbecks Arch Surg 2003; 387 (11-12): 421-426
  • 54 Zannini G, Masciariello S, Pagano G, Sangiuolo P, Zotti G, Iaccarino V. Percutaneous splenic artery occlusion for portal hypertension. A new mechanical technique for hypersplenism. Arch Surg 1983; 118 (08) 897-900
  • 55 Nishida O, Moriyasu F, Nakamura T. et al. Interrelationship between splenic and superior mesenteric venous circulation manifested by transient splenic arterial occlusion using a balloon catheter. Hepatology 1987; 7 (03) 442-446
  • 56 Porter BA, Frey CF, Link DP, Lantz BM, Pimstone NR. Splenic embolization monitored by the video dilution technique. AJR Am J Roentgenol 1983; 141 (05) 1063-1065
  • 57 Yoshida H, Mamada Y, Taniai N. et al. Long-term results of partial splenic artery embolization as supplemental treatment for portal-systemic encephalopathy. Am J Gastroenterol 2005; 100 (01) 43-47
  • 58 Uflacker R, d'Albuquerque LAC, de Oliveira e Silva A, de Freitas JM, Gama-Rodrigues JJ. Embolization to reverse severe recurrent hepatic encephalopathy. Arq Gastroenterol 1988; 25 (Spec No): 21-25
  • 59 Xu RY, Liu B, Lin N. Therapeutic effects of endoscopic variceal ligation combined with partial splenic embolization for portal hypertension. World J Gastroenterol 2004; 10 (07) 1072-1074
  • 60 Khurana S, Dubey ML, Malla N. Association of parasitic infections and cancers. Indian J Med Microbiol 2005; 23 (02) 74-79
  • 61 Palumbo E. Association between schistosomiasis and cancer - a review. Infect Dis Clin Pract 2007; 15: 145-148
  • 62 Kakizoe Y. The influence of Schistosoma mansoni infection on carcinogenesis of mouse livers initiated by N-2-fluorenylacetamide. Kurume Med J 1985; 32 (03) 169-178
  • 63 Toda KS, Kikuchi L, Chagas AL. et al. Hepatocellular carcinoma related to schistosoma mansoni infection: case series and literature review. J Clin Transl Hepatol 2015; 3 (04) 260-264
  • 64 el-Zayadi AR, Badran HM, Barakat EM. et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11 (33) 5193-5198
  • 65 Colecchia A, Scaioli E, Montrone L. et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011; 54 (02) 300-305
  • 66 Gadahadh R, Valenti D, Aljiffry M. et al. Surgery and interventional radiology collaborate on combination therapy in hepatocellular carcinoma. US Gastroenterol Hepatol Rev 2011; (07) 44-49
  • 67 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009; 20 (7, Suppl): S342-S347
  • 68 Hasegawa K, Makuuchi M, Takayama T. et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49 (04) 589-594
  • 69 Molla N, AlMenieir N, Simoneau E. et al. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol 2014; 21 (03) e480-e492
  • 70 Permpongkosol S, Nicol TL, Link RE. et al. Differences in ablation size in porcine kidney, liver, and lung after cryoablation using the same ablation protocol. AJR Am J Roentgenol 2007; 188 (04) 1028-1032
  • 71 Permpongkosol S, Nicol TL, Khurana H. et al. Thermal maps around two adjacent cryoprobes creating overlapping ablations in porcine liver, lung, and kidney. J Vasc Interv Radiol 2007; 18 (02) 283-287
  • 72 Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (125) 1131-1135
  • 73 Llovet JM, Real MI, Montaña X. et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739
  • 74 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Contr 2010; 17 (02) 87-99
  • 75 Lewis AL, Gonzalez MV, Lloyd AW. et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17 (2, Pt 1): 335-342
  • 76 Salem R, Lewandowski RJ, Kulik L. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2